Thus, this transgenic mouse model demonstrates the multiple long-term adverse consequences of low-level TDP-43 overexpression in vivo and demonstrates that such low-level elevation of TDP-43, as observed in ALS and other neurodegenerative conditions, can trigger neurodegenerative clinical phenotypes. The gene discussed is TARDBP; the disease is amyotrophic lateral sclerosis.